Latest

So What’s Holding Up a 100 Year-Old Super Bug Killer?

A non-antibiotic bactericidal treatment for humans was first proven effective in 1919. Ansis Helmanis asks why bacteriophages for human use are not commercially available in the US.

What Time is It? Time to Get a Wearable Strategy

The success of Apple's iWatch is part of the apparently unstoppable rise of wearable technology, in particular health and fitness applications, writes Peter Houston.

New & Noteworthy

Reagan-Udall Foundation Builds Portfolio of Drug Regulatory, Safety Projects

The Reagan-Udall Foundation for the FDA (RUF) is overcoming initial roadblocks and gaining support from a range of public and private organizations, writes Jill Wechsler.

The Market Access Timing Dilemma

Ed Schoonveld highlights the wait confronting lung cancer patients seeking Opdivo in the UK. Can we find room for compromise?

The European Biopharma CEO: A Rare Commodity

A recent survey of European biopharma companies and board members revealed that 80 percent of firms find access to qualified senior executives to be a challenge, with the toughest spot to fill being the "seasoned CEO".

The Adherence Journey: Activating the Patient

Adherence is no longer. The emphasis is now on patient activation, but how significant will this change be? Casey McDonald highlights how mobile tech and data ownership will certainly play a key role.

Industry Responds to FDA Metrics Program

Manufacturers seek gradual rollout of more targeted FDA quality metrics program. Jill Wechsler reports.

New Payment Models: It's Time to Move

Commercial success for pharma brands now demands proactive strategies and interventions, writes Stacie Heller and Peter Weissberg.

From the Editor

The Bogus in Big Data

The big data revolution offers great promise for drug development versus the traditional ways of bringing medicines to market, but there is a larger issue at stake: how to turn data quantity into data quality. William Looney reports.

The Human Chain: The Emerging Pharma Leaders

Amid the release Pharm Exec's Emerging Pharma Leaders 2015, William Looney considers what will determine true leadership in big Pharma in the years ahead.

Europe

A French Reconnection?

France's bid to regain its influence reveals how far Europe is from fully achieving regulatory convergence, writes Reflector.

Closer Encounters: How the Changing Regulatory Environment Is Connecting Regulatory and Safety

The move towards centralization and harmonization means that the regulatory and pharmacovigilance functions can no longer work independently, writes Markus Dehnhardt, Ph.D.

Global

A French Reconnection?

France's bid to regain its influence reveals how far Europe is from fully achieving regulatory convergence, writes Reflector.

Greece: More Than the Next Drug Supply At Risk

The volatility of the nation's crisis could pose greater challenges down the line.

PEspeaks

A French Reconnection?

France's bid to regain its influence reveals how far Europe is from fully achieving regulatory convergence, writes Reflector.

High Drug Prices: What Would Donald Trump Say

A recent poll reported that most Americans think drug prices are unreasonably high, but that 76% of Republicans prefer market competition over government regulation to lower prices. Stephen Littlejohn imagines what Donald Trump would say on the matter.

China Resilient: New Pharma Survey Offers Highly Positive Outlook

A new trade expo survey predicts that it is full speed ahead for a market now too big to be ignored, writes Cameron Sharp.

Advocates Seek to Elevate FDA Patient Access Program

FDA needs to expand and empower its Office of Health & Constituent Affairs and its Patient Liaison Program to better coordinate interactions with individuals and physicians seeking expedited access to experimental therapies, writes Jill Wechsler.

Strategy

Pharma Must Move Beyond Cooperation to True Collaboration

Mike Straw argues that many pharmaceutical companies are mistaking simple cooperation for collaboration.

Taking Flight: Pharm Exec's Top 50 Pharma Companies

Our annual Pharma 50 listing is clear proof that once-small and midsize biopharma companies are joining the top ranks of big Pharma.

The Salix-Valeant Acquisition: "It’s Just a Game"

Sarah Chaney gives an in-depth look at the Salix-Valeant acquisition — how analysts and investors can affect decision-making and potentially drive poor behavior.

Regulatory

A French Reconnection?

France's bid to regain its influence reveals how far Europe is from fully achieving regulatory convergence, writes Reflector.

Reagan-Udall Foundation Builds Portfolio of Drug Regulatory, Safety Projects

The Reagan-Udall Foundation for the FDA (RUF) is overcoming initial roadblocks and gaining support from a range of public and private organizations, writes Jill Wechsler.

Industry Responds to FDA Metrics Program

Manufacturers seek gradual rollout of more targeted FDA quality metrics program. Jill Wechsler reports.

Sales & Marketing

Beyond the Buzzword: Finding Your Patient Centricity

SPONSORED CONTENT. The term “patient centric” has become something of a catch-all term. Cheryl Lubbert looks at the broad range of its application.

When Care Models Collide

What you should know about integrated delivery networks, by Kim White and Christen Buseman.

Why the Emotional Sell is More Critical Than Ever

Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed.

R&D

Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug Adherence

Drug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority